美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

232.02

+2.631.15%

成交量：4,581

成交額：105.91萬

市值：4.66億

市盈率：- -

高：232.10

開：230.06

低：229.59

收：229.39

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.48

換手率：0.23%

股息：0.95

股息率：0.41%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

行業觀察：安進憑藉重磅藥物、生物類似藥及蓄勢待發的研發管線持續積聚勢頭

吉利德科學高管：Q2艾滋病治療市場趨軟，ACA税收補貼取消致部分民眾失去醫保覆蓋

吉利德科學高管：今年暫無計劃進行大規模併購交易

安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發

环球市场播报

吉利德科學於2026年8月4日公布了2026年第二季度財務業績。總收入按年增長10%達到78億美元主要得益於不包括Vek

安進高管表示，預計第三季度運營支出將出現顯著的按月增長。

安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備

安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要

安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。

吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%

吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動

吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元

安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉

TradingKey中文

吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出

安進第二季度銷售額增長9%，利潤超出華爾街預期

吉利德第二季度銷售額增長8%，超出華爾街預期

前瞻：安進股價在財報公布前走高

Vertex 擴大領導團隊，為下一階段增長注入強勁動力

重點關注個股：Palantir、SpaceX、滙豐控股

阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BBH/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":232.024,"timestamp":1789416000000,"preClose":229.3922,"halted":0,"volume":4581,"delay":0,"changeRate":0.011472927152710503,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"盤前交易","change":2.6318,"latestTime":"09-15 06:43:53 EDT","open":230.06,"high":232.1,"low":229.5938,"amount":1059133.20111,"amplitude":0.010925,"askPrice":265.43,"askSize":100,"bidPrice":199.52,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789479000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":232.024,"sharesOutstanding":1976503,"nav":229.3061,"aum":460103384.52,"dividendRate":0.0041,"bidAskSpread":0.001038,"postHourTrading":{"tag":"盘后","latestPrice":231.9013,"preClose":232.024,"latestTime":"19:30 EDT","volume":18,"amount":4175.136,"timestamp":1789428602348,"change":-0.1227,"changeRate":-0.000529,"amplitude":0},"volumeRatio":0.4826983051476247,"impliedVol":0.187,"impliedVolPercentile":0.376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4826983051476247,"shares":2006503,"dividePrice":0.9513,"high":232.1,"amplitude":0.010925,"preClose":229.3922,"low":229.5938,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":232.024,"eps":0,"divideRate":0.0041,"volume":4581,"delay":0,"ttmEps":0,"open":230.06,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":241.1222,"twentyDayClose":218.0411,"sixtyDayClose":188.0998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657511192","title":"行業觀察：安進憑藉重磅藥物、生物類似藥及蓄勢待發的研發管線持續積聚勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511192","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511192?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:24","pubTimestamp":1785918294,"startTime":"0","endTime":"0","summary":"BUZZ-行业观察：安进凭借重磅药物、生物类似药及蓄势待发的研发管线持续积聚势头8月5日-** 生物技术公司安进（Amgen）AMGN.O报告称，第二季度营收 (link) 增长了9%，这主要得益于其胆固醇治疗药物Repatha、骨质疏松症药物Evenity以及罕见病疗法的强劲需求，与此同时，该公司仍在继续推进其实验性减肥药MariTide的研发** 盘前交易中股价小幅上涨从研发到盈利** Tru","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","BK4566","LU2242646821.SGD","BK4581","LU0289739699.SGD","BK4585","IE00BJT1NW94.SGD","BK4533","PJP","AMGN","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2468319806.SGD","BK4588","IE00BFTCPJ56.SGD","LU0122379950.USD","LU0868494617.USD","LU0320765992.SGD","LU2112291526.USD","IBB","IE00B2B36J28.USD","LU0889565916.HKD","BK4599","IBBQ","PBE","TBXU","LU1571399168.USD","SG9999001440.SGD","BK4534","LU0109394709.USD","BK4139","LU0058720904.USD","BIB","LU1983299246.USD","LU1057294990.SGD","LU1061106388.HKD","LU2242652126.USD","IE0009355771.USD","BBH","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108157113","title":"吉利德科學高管：Q2艾滋病治療市場趨軟，ACA税收補貼取消致部分民眾失去醫保覆蓋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108157113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108157113?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:32","pubTimestamp":1785879128,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管在财报电话会议中透露，第二季度艾滋病治疗市场呈现疲软态势。究其原因，部分患者因《平价医疗法案》（ACA）税收补贴取消而失去保险计划，导致市场购买力下降，对整个行业形成冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","IE00B19Z3B42.SGD","LU1674673428.USD","LU0965509101.SGD","LU0861579265.USD","SG9999015945.SGD","LU2089984988.USD","LU1674673691.USD","LU1430594728.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","BMED","SG9999015978.USD","SG9999015952.SGD","BK4566","BK4588","LU1066053197.SGD","BK4550","TMED","LU0965509010.AUD","LU0889565916.HKD","LU2112291526.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU0320765992.SGD","BK4568","IE00B3T34201.USD","LU0122379950.USD","LU1037948897.HKD","BK4585","LU1061106388.HKD","LU1023059063.AUD","IE0002270589.USD","LU0114720955.EUR","IBBQ","BK4139","BK4578","LU0234570918.USD","BIB","LU0289739699.SGD","BK4583","LU1066051498.USD","LU0965509283.SGD","LU1934455863.HKD","LU1778281490.HKD","SG9999015986.USD","BK4532","LU0882574055.USD","LU1585245621.USD","LU1037948541.HKD","LU1057294990.SGD","LU1571399168.USD","LU0965508806.USD","MEDI","GILD","IE00B19Z3581.USD","LU2324357040.USD","TBXU","LU2468319806.SGD","LU1839511570.USD","LU0823416689.USD","LU1934455194.USD","LU0058720904.USD","LU0109394709.USD","LU1934455277.USD","IE00BZ1G4Q59.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100032335","title":"吉利德科學高管：今年暫無計劃進行大規模併購交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1100032335","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100032335?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:12","pubTimestamp":1785877926,"startTime":"0","endTime":"0","summary":"吉利德科学公司高管在电话会议上表示，目前不预计今年会进行额外的大规模并购交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU1778281490.HKD","BK4585","IE00B3T34201.USD","LU0965508806.USD","LU1674673691.USD","LU1934455277.USD","BIB","BK4550","LU0058720904.USD","LU1057294990.SGD","SG9999015986.USD","LU1934455863.HKD","LU0882574055.USD","LU2087621335.USD","BMED","IE00B19Z3B42.SGD","BK4139","SG9999015952.SGD","LU1571399168.USD","BK4583","IBB","LU0289739699.SGD","LU0965509101.SGD","LU0109394709.USD","LU1061106388.HKD","LU1585245621.USD","LU1066053197.SGD","TBXU","MEDI","LU1037948541.HKD","LU0965509283.SGD","LU1023059063.AUD","LU2468319806.SGD","BK4566","LU0320765992.SGD","LU0114720955.EUR","SG9999015978.USD","LU0889565916.HKD","LU2089984988.USD","LU2324357040.USD","LU0965509010.AUD","LU1674673428.USD","BBH","IE00B19Z3581.USD","LU1934455194.USD","SG9999015945.SGD","IBBQ","IE0002270589.USD","BK4588","LU2112291526.USD","TMED","LU1037948897.HKD","IE00B7SZLL34.SGD","BK4532","LU0234570918.USD","IE00BSNM7G36.USD","GILD","LU1430594728.SGD","LU1066051498.USD","LU1839511570.USD","BK4568","LU0122379950.USD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657674945","title":"安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2657674945","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657674945?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:11","pubTimestamp":1785877860,"startTime":"0","endTime":"0","summary":"　　$安进$公司于周二美股收盘后公布财报，第二季度强劲药品销售提振公司利润，因此上调了全年预期，但同时表示将终止一款早期减肥疗法的开发。　　这家生物技术公司周二表示，将停止AMG 513的开发，这是一款目前处于1期研究阶段的潜在减肥疗法。安进称，该研究将完成以跟踪已入组受试者。　　随着AMG 513开发的终止，安进在该领域唯一的候选药物是MariTide，该药目前正在进行针对肥胖、2型糖尿病和慢性体重管理等适应症的3期研究。","market":"fut","thumbnail":"https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkz1673958.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4566","LU0320765992.SGD","IE00BJT1NW94.SGD","NBDS","PINK","IE00BFTCPJ56.SGD","BK4534","RSPH","NVOC","IBBQ","LU0109394709.USD","LU0058720904.USD","PBE","LU0889565916.HKD","LU0122379950.USD","LU2089984988.USD","BBH","LU0289739699.SGD","BK4581","IE0009355771.USD","LU1983299246.USD","IBB","LU1061106388.HKD","BK4139","TRUH","CURE","IE00B4R5TH58.HKD","MEDI","PJP","LU1571399168.USD","LU2242646821.SGD","THNR","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU2468319806.SGD","FXH","IYH","LU0868494617.USD","BK4533","IE00B2B36J28.USD","BK4588","LU2242652126.USD","SG9999001440.SGD","BK4599","TBXU","IE0002141913.USD","FHLC","XLVI","AMGN","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657679605","title":"吉利德科學於2026年8月4日公布了2026年第二季度財務業績。總收入按年增長10%達到78億美元主要得益於不包括Vek","url":"https://stock-news.laohu8.com/highlight/detail?id=2657679605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657679605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:10","pubTimestamp":1785877839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0882574055.USD","LU2089984988.USD","TBXU","IBBQ","LU0109394709.USD","LU1037948541.HKD","BIB","LU1674673428.USD","BK4583","BK4585","LU1023059063.AUD","LU1571399168.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4568","IE00BKVL7J92.USD","LU0889565916.HKD","LU0965509010.AUD","BMED","LU2324357040.USD","LU2468319806.SGD","LU2087621335.USD","LU1934455277.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU1057294990.SGD","LU0058720904.USD","SG9999015978.USD","IBB","LU0234570918.USD","IE00B19Z3B42.SGD","BBH","LU0861579265.USD","IE00BSNM7G36.USD","BK4550","SG9999015952.SGD","LU1839511570.USD","LU0823416689.USD","LU1430594728.SGD","LU0114720955.EUR","LU0965508806.USD","LU0965509283.SGD","TMED","IE00B19Z3581.USD","LU0122379950.USD","GILD","MEDI","LU1778281490.HKD","LU1066051498.USD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657376567","title":"安進高管表示，預計第三季度運營支出將出現顯著的按月增長。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657376567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657376567?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:02","pubTimestamp":1785877379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AMGN","LU0868494617.USD","BK4585","LU0889565916.HKD","IE0002141913.USD","LU1983299246.USD","BIB","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2242646821.SGD","BK4588","LU2242652126.USD","LU2089984988.USD","BK4581","IE00B2B36J28.USD","LU0058720904.USD","SG9999001440.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4566","BK4599","LU1061106388.HKD","BK4534","LU0109394709.USD","IE00BFTCPJ56.SGD","PBE","BK4533","PJP","LU2112291526.USD","LU0320765992.SGD","IBB","IE00BJT1NW94.SGD","BBH","BK4139","TBXU","LU0289739699.SGD","LU1571399168.USD","IE0009355771.USD","IBBQ","LU0122379950.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191538261","title":"安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1191538261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191538261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877307,"startTime":"0","endTime":"0","summary":"安进高管最新表态，公司将继续维持2026年资本支出约26亿美元的预期。这笔资金的核心用途，正是为了扩大制造产能——其中，Maritide的上市准备工作尤为关键。\n26亿美元，一个庞大的数字，却承载着安进对未来市场的信心与布局。产能扩张，尤其是为Maritide的上市铺路，成为了这笔巨额支出的重中之重。这不仅仅是一次简单的投资，更是对战略产品线的全力押注。\n高管在发言中强调，该预期反映了公司对生产能力持续优化的坚定承诺。从长远来看，扩大制造规模不仅是为了满足现有产品的需求，更是为了确保Maritide等关键新药能够顺利推向市场。这一举措，无疑将为公司在竞争激烈的生物制药领域构筑更坚实的护城河。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","IBBQ","IE0009355771.USD","BK4599","IE00B2B36J28.USD","PJP","IE00B4R5TH58.HKD","LU1057294990.SGD","LU0122379950.USD","BK4533","BBH","LU1023059063.AUD","LU2112291526.USD","BK4534","LU2468319806.SGD","BK4139","LU2242646821.SGD","LU1983299246.USD","AMGN","LU2089984988.USD","LU0320765992.SGD","IBB","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU1571399168.USD","BK4581","PBE","TBXU","BK4566","BIB","BK4585","LU2242652126.USD","LU0868494617.USD","LU0058720904.USD","IE0002141913.USD","SG9999001440.SGD","LU1061106388.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128189819","title":"安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要","url":"https://stock-news.laohu8.com/highlight/detail?id=1128189819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128189819?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877299,"startTime":"0","endTime":"0","summary":"安进（Amgen）公司高管在电话会议中透露，第二季度资本支出高达5亿美元。这笔巨额投入的核心驱动力，正是该公司在全美多个制造基地进行的战略布局。投资浪潮席卷了美国的各个生产设施，从而推动了整体资本开支的显著增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0289739699.SGD","BIB","LU0868494617.USD","LU0889565916.HKD","LU0122379950.USD","IBB","TBXU","BK4534","BK4588","LU0109394709.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","BK4599","PBE","LU0058720904.USD","LU2242652126.USD","LU2112291526.USD","LU1057294990.SGD","BBH","AMGN","IE0009355771.USD","LU1023059063.AUD","LU2089984988.USD","IE0002141913.USD","IBBQ","LU1983299246.USD","LU1571399168.USD","BK4581","BK4566","BK4139","BK4585","LU1061106388.HKD","PJP","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","IE00BJT1NW94.SGD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657562205","title":"安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657562205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657562205?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:59","pubTimestamp":1785877188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LU0889565916.HKD","IE00BJT1NW94.SGD","SG9999001440.SGD","AMGN","TBXU","IE0009355771.USD","BK4533","BK4581","LU0320765992.SGD","IE00BJJMRZ35.SGD","BK4566","LU0868494617.USD","BK4139","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4534","FXR","IE00B4R5TH58.HKD","BBH","IBB","LU0058720904.USD","IE00B2B36J28.USD","LU2242652126.USD","PJP","LU2112291526.USD","LU2242646821.SGD","PBE","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","DUSL","LU0122379950.USD","LU1983299246.USD","LU1571399168.USD","BK4585","LU1057294990.SGD","IE0002141913.USD","BK4599","BK4588","LU0289739699.SGD","BIB","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051692","title":"吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051692","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135051692?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876147,"startTime":"0","endTime":"0","summary":"吉利德（Gilead Sciences）高管在电话会议上透露，公司已将全年HIV业务增长预期上调至9%至10%的区间。这一调整较此前8%的增长指引显著提升，展现了公司对该业务领域强劲势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU1571399168.USD","LU0965509283.SGD","LU2112291526.USD","BK4566","IE00B19Z3581.USD","BK4585","LU0965508806.USD","TMED","BK4583","LU0889565916.HKD","LU1585245621.USD","LU0289739699.SGD","LU2468319806.SGD","SG9999015952.SGD","LU2324357040.USD","BK4550","IE00B7SZLL34.SGD","IE0002270589.USD","LU0122379950.USD","LU1934455277.USD","BMED","IE00B19Z3B42.SGD","BK4532","IBB","LU0114720955.EUR","LU0823416689.USD","LU0965509101.SGD","LU1674673691.USD","IE00BSNM7G36.USD","LU1066051498.USD","LU1934455863.HKD","LU1430594728.SGD","LU0861579265.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU1934455194.USD","IBBQ","BK4139","LU0320765992.SGD","LU1037948541.HKD","SG9999015986.USD","BBH","LU2089984988.USD","LU1057294990.SGD","LU0234570918.USD","LU1061106388.HKD","GILD","LU1778281490.HKD","LU0109394709.USD","BIB","LU2087621335.USD","LU0965509010.AUD","LU1839511570.USD","MEDI","BK4578","IE00BKVL7J92.USD","BK4568","IE00B3T34201.USD","BK4588","LU0882574055.USD","LU1066053197.SGD","SG9999015945.SGD","LU1037948897.HKD","TBXU","SG9999015978.USD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145483121","title":"吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1145483121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145483121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876146,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管透露，针对其重磅细胞疗法Anito-Cel的上市准备工作已全面铺开，目前距离美国食品药品监督管理局（FDA）设定的PDUFA目标日期仅剩五个月时间。这一消息源自公司近期召开的电话会议。\n在会议中，高管进一步强调，公司正紧锣密鼓地推进各项筹备事项，以确保一旦获批，该疗法能够迅速进入市场。Anito-Cel作为一种前沿的细胞治疗产品，被视为吉利德在肿瘤学领域布局的关键一环。随着最终审批日期的临近，市场对这款疗法的商业化前景给予高度关注，而吉利德方面则展现出对既定时间表与执行能力的充分信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673691.USD","BK4578","IE00B19Z3581.USD","LU2112291526.USD","SG9999015945.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","LU0965509010.AUD","BIB","BMED","LU0861579265.USD","BBH","IBB","LU0122379950.USD","LU0823416689.USD","LU1066051498.USD","LU1061106388.HKD","LU1778281490.HKD","LU2089984988.USD","IE00B3T34201.USD","LU0058720904.USD","TBXU","BK4532","SG9999015986.USD","LU2087621335.USD","LU1057294990.SGD","SG9999015952.SGD","BK4568","BK4588","IE00B19Z3B42.SGD","LU0965508806.USD","BK4585","LU0109394709.USD","GILD","LU1585245621.USD","BK4550","LU1571399168.USD","LU0320765992.SGD","LU2324357040.USD","BK4566","LU0289739699.SGD","LU0965509283.SGD","LU0965509101.SGD","LU1037948541.HKD","LU1934455194.USD","LU1037948897.HKD","IE00B7SZLL34.SGD","LU2468319806.SGD","SG9999015978.USD","LU1066053197.SGD","LU0882574055.USD","LU1430594728.SGD","LU1934455277.USD","LU0114720955.EUR","LU0234570918.USD","TMED","IE00BSNM7G36.USD","LU1934455863.HKD","LU1674673428.USD","IBBQ","IE0002270589.USD","LU0889565916.HKD","LU1839511570.USD","BK4583","MEDI","BK4139","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163992816","title":"吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163992816","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163992816?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:17","pubTimestamp":1785874678,"startTime":"0","endTime":"0","summary":"8月4日，吉利德科学（Gilead Sciences）公布第二季度产品销售额达76.27亿美元。第二季度调整后每股收益为-6.75美元，优于IBES预估的-7.24美元。","market":"us","thumbnail":"https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","LU0289739699.SGD","BK4532","LU2087621335.USD","BK4550","LU1037948541.HKD","LU1934455194.USD","LU1934455863.HKD","BK4139","LU1674673428.USD","TMED","LU0823416689.USD","IBB","IBBQ","LU2324357040.USD","LU0122379950.USD","TBXU","SG9999015986.USD","LU0882574055.USD","LU1839511570.USD","BK4588","LU0889565916.HKD","LU1778281490.HKD","LU1674673691.USD","LU1585245621.USD","LU2112291526.USD","LU1023059063.AUD","LU2468319806.SGD","LU0965508806.USD","IE00BKVL7J92.USD","BK4583","IE00BSNM7G36.USD","LU1037948897.HKD","LU0234570918.USD","LU0965509101.SGD","LU1061106388.HKD","LU1066051498.USD","SG9999015952.SGD","LU1066053197.SGD","LU0114720955.EUR","BMED","IE00BZ1G4Q59.USD","LU1934455277.USD","LU0965509283.SGD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU0058720904.USD","SG9999015945.SGD","BBH","SG9999015978.USD","BK4568","LU1057294990.SGD","IE00B3T34201.USD","MEDI","IE0002270589.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","LU2089984988.USD","LU1571399168.USD","BK4578","LU0109394709.USD","LU0965509010.AUD","LU0861579265.USD","BK4566","GILD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627865","title":"安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627865","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627865?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:16","pubTimestamp":1785874591,"startTime":"0","endTime":"0","summary":"• 安进公布的第二季度业绩超出了市场对营收和每股收益的共识预期。\n• 一款代谢健康候选药物的积极中期临床数据推动了其股价上涨。\n• 全年营收达到367.5亿美元，该公司的净利润排名位列第十。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262074405-market-movers-amgn-20260804","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","SG9999001440.SGD","LU1057294990.SGD","LU2468319806.SGD","BIB","IE0009355771.USD","LU2089984988.USD","BK4588","AMGN","LU0289739699.SGD","PBE","LU1061106388.HKD","LU0320765992.SGD","BBH","IE0002141913.USD","IE00BFTCPJ56.SGD","TBXU","IE00B4R5TH58.HKD","LU2242652126.USD","LU0122379950.USD","IBB","PJP","BK4581","IE00BJJMRZ35.SGD","BK4139","BK4599","BK4533","LU2242646821.SGD","LU0889565916.HKD","LU1983299246.USD","LU1571399168.USD","BK4585","LU0109394709.USD","LU0868494617.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IBBQ","LU0058720904.USD","BK4534","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108344321","title":"吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1108344321","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108344321?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873878,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）最新季度业绩揭晓。数据显示，公司调整后每股收益为-6.75美元。这一数字背后，折射出近期收购活动所产生的重大财务影响——具体而言，每股9.08美元的知识产权研发成本与税务费用被计入。这些支出，均与公司近期完成的收购交易紧密相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","LU0965509101.SGD","LU2324357040.USD","BK4550","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","LU2089984988.USD","IBBQ","BBH","IE00BSNM7G36.USD","LU1037948897.HKD","LU1839511570.USD","BK4578","BK4588","LU0889565916.HKD","LU1674673691.USD","LU1674673428.USD","BK4566","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU1057294990.SGD","LU1061106388.HKD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","LU1934455194.USD","LU1934455863.HKD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU0234570918.USD","LU1430594728.SGD","BIB","LU0965509283.SGD","LU0122379950.USD","BK4568","LU0861579265.USD","LU0965509010.AUD","LU1023059063.AUD","LU1037948541.HKD","BK4585","LU1585245621.USD","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","LU2468319806.SGD","BK4139","IE00B19Z3B42.SGD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569101","title":"安進第二季度銷售額增長9%，利潤超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569101?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873843,"startTime":"0","endTime":"0","summary":"安进第二季度销售额增长9%，利润超出华尔街预期经调整的每股收益为6.29美元，超出分析师预期上调全年营收和利润预期安进公司停止开发第二款实验性减肥药AMG 513Deena Beasley路透8月4日-安进公司周二公布，受降胆固醇药物Repatha、骨质疏松药物Evenity以及罕见病药物需求推动，第二季度销售额增长9%。季度营收同比增长10%，达到101亿美元，超过了华尔街94.2亿美元的平均预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","AMGN","LU0058720904.USD","LU2242652126.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IBB","LU0289739699.SGD","BK4599","LU2089984988.USD","TBXU","IBBQ","BBH","BK4588","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4566","LU1571399168.USD","LU1057294990.SGD","LU1061106388.HKD","SG9999001440.SGD","LU2112291526.USD","PJP","LU0109394709.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","BIB","04332","BK4534","LU0122379950.USD","LU2242646821.SGD","LU1023059063.AUD","BK4585","LU0868494617.USD","IE00B4R5TH58.HKD","BK4581","PBE","LU2468319806.SGD","BK4139","LU1983299246.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657820569","title":"吉利德第二季度銷售額增長8%，超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657820569","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657820569?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873759,"startTime":"0","endTime":"0","summary":"据LSEG数据显示，该公司总营收增长10%至78亿美元，超出华尔街预期的74亿美元。第二季度，吉利德公布经调整后每股亏损为6.75美元，而华尔街分析师平均预期为7.24美元。另一款较早上市的艾滋病口服药Descovy的季度销售额猛增48%，达到9.67亿美元，增幅超出预期。吉利德表示，其肝病产品组合的销售额增长10%，达到8.77亿美元，而细胞疗法产品的销售额则下降14%，至4.17亿美元，这反映出市场竞争加剧。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4139","LU1037948897.HKD","LU1061106388.HKD","TBXU","GILD","LU0965509101.SGD","LU1066053197.SGD","SG9999015952.SGD","IE00B3T34201.USD","LU0965509283.SGD","BIB","SG9999015978.USD","BBH","LU1674673428.USD","LU1934455277.USD","LU2089984988.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU2324357040.USD","LU0882574055.USD","LU2468319806.SGD","BMED","LU0320765992.SGD","BK4568","MEDI","SG9999015945.SGD","IE00B19Z3581.USD","LU1585245621.USD","BK4583","LU0889565916.HKD","BK4588","IBBQ","LU1571399168.USD","BK4585","LU0965509010.AUD","LU1066051498.USD","BK4566","IBB","LU0114720955.EUR","LU0234570918.USD","LU1778281490.HKD","TMED","LU0823416689.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568090","title":"前瞻：安進股價在財報公布前走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568090","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568090?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 01:30","pubTimestamp":1785864614,"startTime":"0","endTime":"0","summary":"BUZZ-前瞻：安进股价在财报公布前走高8月4日-** 安进AMGN.O股价周二上涨2.2%，该公司将于收盘后公布季度财报，投资者正密切关注其试验性减肥药的最新进展** 据伦敦证券交易所集团（LSEG）预测，这家生物技术公司预计将公布季度营收增长3%至94.2亿美元，而调整后每股收益则可能从6.02美元降至5.62美元** 在过去8个季度中，AMGN有7个季度达到了或超过了每股收益预期，最近一次未","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4S4411RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","PJP","IE0002141913.USD","BK4581","PBE","LU2242652126.USD","AMGN","IE00BFTCPJ56.SGD","LU0868494617.USD","TBXU","BK4585","BK4533","BIB","BK4599","LU2242646821.SGD","LU1023059063.AUD","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU0122379950.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1061106388.HKD","LU2089984988.USD","LU0320765992.SGD","LU0289739699.SGD","BK4566","BK4139","LU1571399168.USD","LU1057294990.SGD","BK4588","LU1983299246.USD","IE0009355771.USD","IBBQ","IE00BJT1NW94.SGD","LU0109394709.USD","LU0889565916.HKD","IE00B2B36J28.USD","BK4534","LU0058720904.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 擴大領導團隊，為下一階段增長注入強勁動力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117517951?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王，2026年8月4日——全球间接税与合规领域的“决策到防御”先锋，Vertex Inc.，今日宣布其领导团队迎来三位新成员，旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入，将通过对人才、区域运营及技术创新的领导力扩展，进一步强化 Vertex 的全球增长战略。在 Vertex，她将负责全球人才与企业文化战略，构建起推动业务规模化发展所需的人才储备和组织能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","BK4604","LU2362541513.USD","IE00B4R5TH58.HKD","LU1093756325.SGD","LU2417539215.USD","IE0002141913.USD","LU2462157665.USD","BK4099","TISI","LU1585245621.USD","LU2362540622.SGD","SGXZ57979304.SGD","LU2324357040.USD","TM","LU0256863811.USD","LU0109394709.USD","IE0002270589.USD","GNMX","IE00B894F039.SGD","LU0757428866.USD","03160","PBE","LU0289739699.SGD","LU2468319806.SGD","IE00BFTCPJ56.SGD","SG9999001176.SGD","BK4533","TBXU","SG9999001176.USD","IE00B19Z9P08.USD","BK4555","LU0058720904.USD","LU0823416689.USD","BK4023","LU2089984988.USD","LU1674673428.USD","BK4234","VRTX","PW","IE00B19Z9Z06.USD","IE00B2B36J28.USD","IDNA","BBH","IE00B19Z3B42.SGD","IE00BZ9MQY76.HKD","BK4585","IE00BJT1NW94.SGD","LU1674673691.USD","SG9999013999.USD","IE0009355771.USD","LU1093756168.USD","LU2237438978.USD","BK4588","IBB","BK4567","LU2362541273.HKD","LU0417517546.SGD","LU1035775433.USD","LU0432979614.USD","BK4084","LU1069344957.HKD","LU1559883803.SGD","BIB","LU0234570918.USD","LU2456880835.USD","BK4120","LU1815336091.USD","BK4532","LU0320765992.SGD","LU0566484027.USD","BK4139","VERX","LU0889565916.HKD","LU0061475181.USD","LU2236285917.USD","LU1778281490.HKD","IBBQ","IE00BJJMRZ35.SGD","IE00B19Z3581.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103561229","title":"重點關注個股：Palantir、SpaceX、滙豐控股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103561229","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103561229?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:28","pubTimestamp":1785835721,"startTime":"0","endTime":"0","summary":"**Palantir Technologies **：这家软件公司昨日盘后公布了强劲的财报，业绩表现亮眼，推动其盘前股价飙升逾15%。财报发布后，其股价微幅上涨。**汇丰控股 **：这家英国银行公布季度利润增长，并宣布了高达10亿美元的股票回购计划，但由于回购规模令部分投资者感到失望，其股价小幅走低。Segro股价小幅上扬，而安博盘前股价则基本持平。**辉瑞 、默沙东 、安进  与 BioNTech **：这些制药公司将在今日美股开盘前公布财报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107168.USD","QQQA","LU1852331112.SGD","IE00BJJMRY28.SGD","LU1303367103.USD","LU0726765562.USD","BK4023","LU0980610538.SGD","CHAT","PBE","LU0133085943.USD","FHLC","LU0127658192.USD","LU1803068979.SGD","IE00BJTD4V19.USD","LEGR","LU0477156953.USD","IE00BKVL7J92.USD","LU1066051811.HKD","SG9999015358.SGD","LU2089985449.USD","BK4007","GDOC","LU0289739699.SGD","LU0238689110.USD","BK4555","PLTR","SG9999001440.SGD","JRE","LU0792757196.USD","SG9999001176.USD","BK4612","IE00BSNM7G36.USD","LU0234572021.USD","LU0256863811.USD","LU0203345920.USD","LU0417517546.SGD","BP.UK","LU1116320737.USD","GQRE","GUNZ","LU2324357040.USD","LU0965509010.AUD","LU1035773651.USD","LU1732799900.SGD","LU0648001328.SGD","LU0124676726.USD","ILDR","FAI","BK4566","LU1074936037.SGD","LU1923623000.USD","LU2461242641.AUD","LU0048584097.USD","LU1732800096.USD","BK4533","LU2860962120.EUR","IGV","LU1934455194.USD","BK4573","BK4551","BK4604","PLTU","IE0009356076.USD","LU1267930813.SGD","LU0211331839.USD","SG9999015341.SGD","LU1291159041.SGD","LU1093756325.SGD","REET","04332","BK4610","BK4504","CLIM","LU2279689827.SGD","AMDG","IBB","LU2360106780.USD","LU0689626769.HKD","ERET","IE0009355771.USD","LU2242649171.HKD","CRED","LU1244550221.USD","LU0208291251.USD","BIB","LU0198837287.USD","LU1267930227.SGD","BK4548","BK4554","RXL","BK4139","LU1917777945.USD","LU2108987350.USD","LU2265009873.SGD","LU2360032135.SGD","BK4613","ORBX","LU1244550577.SGD","MCD","LU2112291526.USD","AMDW","IYH","LU1116320901.HKD","LU0251132253.USD","IE00BJT1NW94.SGD","BBRE","IE0004445239.USD","LU1989771016.USD","LU0306806265.USD","SGXZ81514606.USD","BBH","SPRE","PSI","TRUR","SG9999002232.USD","IE00B19Z9Z06.USD","LU2458330169.SGD","LU0109394709.USD","BK4141","JDOC","AMD","IXJ","LU0225284248.USD","LU0390134368.USD","BK4512","IHE","LU1941712264.USD","TRUH","HSBC","IE00B19Z3581.USD","LU0496365809.HKD","LU1430594728.SGD","IE00BN8TJ469.HKD","LOFF","WUGI","BK4534","DTRE","LU1571399168.USD","LU2250418816.HKD","TTEQ","SCHH","PLYY","IE00BLSP4239.USD","RWO","LU1951198990.SGD","IE00B894F039.SGD","LU2290526834.HKD","SPCQ","PLTG","PTIR","DAMD","FRI","TM","SOXX","IE00B19Z9P08.USD","AMDL","LU0642271901.SGD","AMDU","LU1983299246.USD","LU0823421416.USD","LU2355687059.USD","LU0432979614.USD","LU1880398554.USD","LU2347655073.USD","BK4209","LU2491049909.HKD","BK4588","LU0861579265.USD","LU2362541513.USD","VGSR","DFAR","BK4099","TRFK","SOXY","PLTD","LU2491050154.USD","JPRE","00005","INDS","AMGN","BK4614","LU1066051498.USD","LU2125154778.USD","LU2089984988.USD","LU2931357623.SGD","LU0106261372.USD","LU2054465674.USD","AIQ","PPH","LU0976567544.SGD","TEK","LU1316542783.SGD","LU0823434740.USD","LU0795875086.SGD","RITA","BK4224","LU2596442595.SGD","LU0889565916.HKD","SPCH","LU0320765489.SGD","SSPC","SHLD","CNAV","PJP","LU1989772923.USD","SPOT","LU2361045086.USD","03160","LU1162221912.USD","BK4585","BK4529","DFGR","LU0321505439.SGD","LU0306807586.USD","LU1923622614.USD","IE00B5949003.HKD","RNTY","XLRE","IE00BZ9MQY76.HKD","LU0965509283.SGD","LU1232071149.USD","LU0098860793.USD","LU1037948897.HKD","SG9999014559.SGD","LU0965509101.SGD","LU1718418525.SGD","PLTI","BK4535","IE00BMPRXN33.USD","LU1951200564.SGD","LU1804176565.USD","IYR","RWR","LU2023250504.SGD","XNTK","LU0889566641.SGD","BAI","LU1585245621.USD","LU0719512351.SGD","LU1894683264.USD","PLTY","LU0979878070.USD","AIS","LU2491050071.SGD","PSR","LU0321505868.SGD","PFE","IE00BQXX3C00.GBP","LU0081259029.USD","SMHX","LU1861559042.SGD","SG9999001424.SGD","WISE","ICF","LU1989772840.SGD","IE00BJTD4N35.SGD","URE","LU0456855351.SGD","SG9999014575.USD","BK4516","LU0211326755.USD","LU1699723380.USD","SG9999001176.SGD","IE00BJJMRZ35.SGD","LU2133065610.SGD","BK4171","SG9999013999.USD","BK4108","SPCX","LU1066051225.USD","PPTY","CHPS","LU1861220033.SGD","LU0211326839.USD","IE00BZ1G4Q59.USD","IE00BFTCPJ56.SGD","LU0859254822.USD","REIT","LU0070302665.USD","FTXH","IE0004445015.USD","LU1242518931.SGD","LU2361044865.SGD","IE00B2B36J28.USD","LU0868494617.USD","LU2347655156.SGD","IE00BFSS7M15.SGD","LU0912757837.SGD","LU2242652126.USD","BK4521","LU0265550946.USD","GAMR","BK4207","LU1066053197.SGD","TBXU","LU2236285917.USD","IE00BQXX3F31.USD","LU1974910355.USD","SPCF","LU0823421333.USD","LU0265550359.USD","MARS","LU1037948541.HKD","SG9999002224.SGD","LU2125909593.SGD","LU1894683348.USD","AMYY","SPCG","LU0985320562.USD","LU1201861249.SGD","BK4089","IE0002270589.USD","LU0795875169.SGD","LU2462591350.SGD","SG9999014542.SGD","LU1861215975.USD","LU2361044949.HKD","LU0058720904.USD","IYRI","LU0823434583.USD","LU0823416689.USD","HRTS","LU0786609619.USD","PLD","BK4581","IE00BFSS8Q28.SGD","LU0210536198.USD","LU1934455277.USD","PLTA","LU0056508442.USD","IE00BBT3K403.USD","IE00B7KXQ091.USD","BK4568","FTXL","LU2458330243.SGD","LU0174119429.USD","LU0170899867.USD","SMH","USXF","LU1989764664.SGD","LU2264538146.SGD","LU1989764748.USD","IE00BMPRXQ63.HKD","OZEM","LU0868494708.USD","LU0203347892.USD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU0052756011.USD","SG9999003800.SGD","LU0942090050.USD","IBBQ","ARTY","IE00BLSP4452.SGD","SGXZ99366536.SGD","LU2468319806.SGD","LU0130102774.USD","IE00BJJMRX11.SGD","SPAX","LU0889565833.HKD","LU1941712348.USD","LU1983260115.SGD","SPOG","LU1064131342.USD","AMDD","PLT","LU0128525689.USD","USRT","BK4550","XLV","BK4605","LU0266013472.USD","IE00B1BXHZ80.USD","LU1934455863.HKD","LU2023250843.SGD","PLOO","SGXZ51526630.SGD","LU0320765992.SGD","LU2125154935.USD","LU2106854487.HKD","LU1057294990.SGD","LU2357627491.SGD","BK4592","AIPI","LU2896262040.SGD","LU0006306889.USD","LU1244550494.USD","LU0965508806.USD","LU0122379950.USD","LU2125909247.SGD","BK4599","BK4559","VNQ","BK4543","IE0001KFT4U8.USD","IE00BQXX3D17.EUR","IETC","VHT","LU2433249047.HKD","LU1988902786.USD","LU0310800965.SGD","LU2098885051.SGD","IE00B3T34201.USD","HSBH","WARP","AVRE","LU0320765646.SGD","LU0225771236.USD","SGXZ57979304.SGD","BK4575","BK4547","BK4532","IE00BMPRXR70.SGD","LU1883839398.USD","MRK","LU1929549753.HKD","AMDS","LU0082616367.USD","WTRE","LU2247934214.USD","IE00B4R5TH58.HKD","LU1093756168.USD","IE000M9KFDE8.USD","DPRE","SPCM","LU0274383776.USD","LU0130517989.USD","LU1023059063.AUD","LU1880398471.USD","AMDY","LU0985481810.HKD","BMED","SG9999014567.USD","BK4571","IE0002141913.USD","LU2362541273.HKD","WSPC","PLTZ","LU0109392836.USD","EYES","LU2242646821.SGD","LU2362540622.SGD","BNTX","FREL","LU1861558580.USD","LU1061106388.HKD","AMUU","BK4567","PLTW","LU1069347547.HKD","PAWZ","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656080539","title":"阿斯利康擬與百時美施貴寶4000億美元重組傳聞背後：專利懸崖、產品短板倒逼，AZ端反對聲大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656080539","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656080539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 17:26","pubTimestamp":1785835565,"startTime":"0","endTime":"0","summary":"蓝鲸新闻记者联系了阿斯利康方面，对方拒绝对此置评。此外，BMS有神经管线与Eliquis后续心血管资产，可补足AZ在相关领域的短板。据BMO资本在研报中指出，两家公司都没有足够的财务实力直接收购对方，预计阿斯利康能掏出约370亿美元，而百时美施贵宝约为320亿美元，远低于搞定一桩价值4000亿美元合并所需的资金。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785835141389493693","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4588","LU0267386448.USD","BBH","PJP","LU1032466523.USD","MEDI","JDOC","BBP","LU1670710588.SGD","LU1868836591.USD","LU2596442595.SGD","LU0128525929.USD","LU2237443382.USD","LU0432979614.USD","LU2089984988.USD","LU1585245621.USD","LU0321505439.SGD","LU2237443895.HKD","BK4559","LU2462157665.USD","TRUH","LU1868837300.USD","LU1093756168.USD","LU1670711123.USD","LU0321505868.SGD","RSPH","LU0868494617.USD","TMED","IE00B2B36J28.USD","APXH","FTXH","LU2242646821.SGD","AZNH","AZN","LU0225284248.USD","LU1868836914.USD","FXH","BMY","LU0882574055.USD","PPH","IE00BJJMRZ35.SGD","IYH","LU0985481810.HKD","BME","GSKH","AZ","FHLC","LU1093756325.SGD","IHE","PBPH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":187,"code":"91000000","status":"200"}]}}